The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson’s Disease

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 21, 38 Issues, 2014


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 5th of 59 in Chemistry & Medicinal
  • 41st of 261 in Pharmacology & Pharmacy
  • 80th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK
Email: cmc@benthamscience.org

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.07
5 - Year: 4.471

The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson’s Disease

Author(s): M. Jörg, P. J. Scammells and B. Capuano

Affiliation: Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia

Abstract

Herein, we present an overview of the historic development of drugs for the treatment of Parkinson’s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. Commencing with levodopa, a precursor of the neurotransmitter dopamine developed in the 1960s, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson's disease, to more recent studies of the adenosine receptor, a promising target for the treatment of Parkinson’s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of the receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress has changed the direction of the research in academia and industry and will form the pillars for novel and exciting discoveries in this field

Keywords: Adenosine A2A receptor antagonist, bivalent ligand, dopamine, dopamine D2 receptor agonist, G protein-coupled receptor, levodopa, non-dopaminergic drug, Parkinson's disease

Purchase Online Rights and Permissions

Article Details

Volume: 21
First Page: 1
Last Page: 23
Page Count: 23
DOI: 10.2174/1389200215666140217110716
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science